Catch up on insights into the global development of breast cancer treatments in the global spotlight.
|Videos|February 21, 2017
Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer
Author(s)Kevin Kalinsky, MD
Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.
Advertisement
Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.
Some patients with breast cancer are unable to tolerate MRIs, which makes non-invasive optical imaging beneficial, explains Kalinsky. There is no intravenous injection needed, allowing it to be relatively quick and inexpensive.
Advertisement
Related to this article
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
3
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
4
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
5